Related Experiment Video
Updated: Sep 29, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
[T lymphocyte alpha/beta and gamma/delta in peripheral blood of children with acute lymphoblastic leukemia]
Bogdan Mazur1, Iwona Wylezoł, Danuta Sońta-Jakimczyk
1Katedra i Klinika Hematologii Dzieciecej i Chemioterapii SAM, ul. 3 Maja 13/15, 41-800 Zabrze.
Insights
Children with low-risk acute lymphoblastic leukemia (ALL) experience immune system recovery 12 months after chemotherapy. This study monitored immune cell recovery post-treatment in pediatric ALL patients.
Area of Science:
- Pediatric Oncology
- Immunology
Background:
- Improved treatment outcomes for acute lymphoblastic leukemia (ALL) necessitate understanding long-term effects on the pediatric immune system.
- Assessing immune recovery is crucial for children undergoing therapy for low-risk ALL.
Purpose of the Study:
- To evaluate the immune system status in children diagnosed with low-risk ALL.
- To track immune system changes during and 12 months after completing therapy.
Main Methods:
- The study involved 41 children with low-risk ALL.
- Lymphocyte immune phenotype was analyzed using flow cytometry (FACScan) with monoclonal antibodies.
- Patients were assessed during treatment (n=16) and 12 months post-therapy (n=25).
Main Results:
- Intensive chemotherapy significantly reduced leukocyte and lymphocyte counts, including their subpopulations.
- Immune cell numbers and function showed recovery in most patients by 12 months after therapy cessation.
Conclusions:
- The pediatric immune system demonstrates substantial recovery within 12 months after completing chemotherapy for low-risk ALL.
- This recovery period appears sufficient for restoring immune function in this patient group.
Abstract:
The improvement in acute lymphoblastic leukemia (ALL) children treatment results in the need of examining their immune system after therapy. The purpose of the research was the immune system evaluation in children with low risk ALL diagnosis, during the treatment and twelve months after therapy. The examined material included 41 children. A group of 16 patients was examined during the above the treatment, immediately after intensive chemotherapy. The other 25 patients were examined twelve months after the completion of therapy. The lymphocyte immune phenotype was examined with FACScan flow cytometer using monoclonal antibodies. The study confirmed the intensive chemotherapy significantly decreases the number of leukocytes, lymphocytes and their subpopulations. The period of 12 months after cessation of the chemotherapy is sufficient to recover the immune system function in all examined low risk ALL children.
